Discover how precision oncology companies are using AI and patient-relevant biology to reduce clinical trial failures in cancer.
The post Rethinking precision oncology drug development: AI and tumor biology for smarter therapeutic programs appeared first on Labiotech.eu.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
Washington Dept. Health & Social Services Insider Breach Affects 8,600 Individuals
The Washington Department of Social and Health Services (DSHS) has identified an insider data breach involving unauthorized access to the protected health information of approximately 8,600
